As per the terms of the agreement, Sanofi-aventis will have access to Belfer’s cancer target identification and validation platform, and translational medicine capabilities.
Belfer has licensed Sanofi-aventis an option to manufacture, develop and commercialise compounds directed at the targets identified and validated under the research collaboration.
Sanofi-aventis is expected to pay a sum of $33m as an upfront payment and research funding for a minimum of three years.
Dana Farber will also be entitled to preclinical, clinical, and commercial milestone payments and royalties on sales of the commercialised products.